sal0140
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 9, 2025 (NCT07051603)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytochrome P450 11B2INHIBITOR
CYP11B2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07051603 | Phase 1 | Jun 9, 2025 | Shenzhen Salubris Pharmaceuticals Co., Ltd., Southern Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1